



Apersy

Value | Commercial | Access

January 2023 Market
Access news recap

READING LIST edition*

Evidence & Access



[Another recommendation from NICE's Early Value Assessment \(EVA\) pilot: genetic test to prevent newborn babies going deaf](#)

[After 6-year managed access agreement data collection, NICE recommends routine NHS funding for ataluren \(Translarna\) for Duchenne muscular dystrophy gene therapy ataluren in final draft guidance](#)

[Yet more concerns about the EU JCA implementation - this time from German industry bodies... \[GERMAN\]](#)

Digital & AI



[HAS in France opens a dedicated platform service for reimbursement submissions for Digital Medical Devices and telemonitoring technologies \[FRENCH\]](#)

[Second GKV-SV DiGA report \(Germany\): Great potential for DiGAs to improve patient care, but sickness funds criticise high prices and limited evidence \[GERMAN\]](#)

Pricing & Financing



[ICER \(US\) Identifies Most Significant 2021 US Drug-Price Hikes Unsupported by New Clinical Evidence](#)

[Former CEO says Biogen 'shot themselves in the foot' by deciding to charge \\$56,000 for its controversial Alzheimer's drug](#)

[In a tough fundraising climate for startups, conversations at JPM 2023 shift to partnerships](#)

For more updates on how payers think about value and evaluate health tech products, connect or get in touch



contact@apersy.com



www.apersy.com



www.linkedin.com/company/apersy/